Babler Martin
- SEC CIK
- 0001435618
No open-market purchases or sales filed in the past year.
Current role at each company
- MPLT MapLight Therapeutics, Inc.Directoras of Jun 25, 2026
- PRLD Prelude Therapeutics IncDirectoras of Jun 10, 2026
- ALMS Alumis Inc.President, CEO and Chairmanas of Jan 28, 2026
- ETNB 89bio, Inc.Directoras of Oct 30, 2025
- NGNE Neurogene Inc.Directoras of Jun 9, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Babler Martin as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ALMS Alumis Inc.
President, CEO and Chairman1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 3, 2025 (view filing) | Apr 1 | 2 days | Babler MartinPresident, CEO and Chairman | PPurchase | +15.7K | $6.44 | +$100.8K | +17.2%106.5K after |